MAZEMaze Therapeutics, Inc.

$29.59

$13.1452 weeks$51.83

Price

$29.59+122%1Y

1M+7.0%1Y+122%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Below average

3/10

Value22

Quality35

Momentum78

Growth-

Strongest Momentum, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with kidney and metabolic diseases. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants associated with health and disease and then determine how these drive risk for and protection against disease in specific patient groups through a process we refer to as variant functionalization.

In the company’s own words · 10-K filed Mar 25, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$1.42B

1Y Return+122%

5Y Return-

Maze Therapeutics, Inc. (MAZE) reported revenue of $0 in Q2 2026 (quarter ended June 30, 2026). That came with net loss of $45M.